Business Description
Vicore Pharma Holding AB
ISIN : SE0007577895
Compare
Compare
Traded in other countries / regions
VICO.Sweden6Y4.Germany IPO Date
2020-07-21Description
Vicore Pharma Holding AB is as a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Its C21 is a small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2a development for IPF. The company also has an investigational medical device in clinical development namely, Almee which is a digital therapeutic leveraging cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.91 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 26.35 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -6.4 | |||||
| 3-Year EPS without NRI Growth Rate | -5.9 | |||||
| 3-Year FCF Growth Rate | -4.5 | |||||
| 3-Year Book Growth Rate | -11.4 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 52.27 | |||||
| 9-Day RSI | 51.79 | |||||
| 14-Day RSI | 44.4 | |||||
| 6-1 Month Momentum % | -56.34 | |||||
| 12-1 Month Momentum % | -48.66 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 11.98 | |||||
| Quick Ratio | 11.98 | |||||
| Cash Ratio | 11.68 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -22.7 | |||||
| Shareholder Yield % | -17.98 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -215.82 | |||||
| Net Margin % | -191.92 | |||||
| FCF Margin % | -123.44 | |||||
| ROE % | -44.5 | |||||
| ROA % | -40.5 | |||||
| ROIC % | -460.39 | |||||
| ROC (Joel Greenblatt) % | -816260.16 | |||||
| ROCE % | -44.44 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 9.49 | |||||
| PB Ratio | 2.28 | |||||
| Price-to-Tangible-Book | 2.18 | |||||
| EV-to-EBIT | -8.42 | |||||
| EV-to-Forward-EBIT | -4.75 | |||||
| EV-to-EBITDA | -8.42 | |||||
| EV-to-Forward-EBITDA | -4.75 | |||||
| EV-to-Revenue | 16.22 | |||||
| EV-to-FCF | -12.89 | |||||
| Price-to-Net-Current-Asset-Value | 2.18 | |||||
| Price-to-Net-Cash | 2.18 | |||||
| Earnings Yield (Greenblatt) % | -11.88 | |||||
| FCF Yield % | -6.63 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Vicore Pharma Holding AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 9.211 | ||
| EPS (TTM) (€) | -0.157 | ||
| Beta | -0.06 | ||
| Volatility % | 76.09 | ||
| 14-Day RSI | 44.4 | ||
| 14-Day ATR (€) | 0.027356 | ||
| 20-Day SMA (€) | 0.6924 | ||
| 12-1 Month Momentum % | -48.66 | ||
| 52-Week Range (€) | 0.604 - 2.042561 | ||
| Shares Outstanding (Mil) | 223.47 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Vicore Pharma Holding AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Vicore Pharma Holding AB Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Vicore Pharma Holding AB Frequently Asked Questions
What is Vicore Pharma Holding AB(STU:6Y4)'s stock price today?
The current price of STU:6Y4 is €0.74. The 52 week high of STU:6Y4 is €2.04 and 52 week low is €0.60.
When is next earnings date of Vicore Pharma Holding AB(STU:6Y4)?
The next earnings date of Vicore Pharma Holding AB(STU:6Y4) is 2024-11-05.
Does Vicore Pharma Holding AB(STU:6Y4) pay dividends? If so, how much?
Vicore Pharma Holding AB(STU:6Y4) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers